CD8A and neoplasm: For instance, an inspiring RGD-based nanoparticle vaccine, encapsulating an E749-57-HSP110 fusion expression plasmid, effectively targets and penetrates TC-1 tumor cells, stimulating robust CD8+ T cell activation and IFN-γ production.